menu
    • menu
    [{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Tasmanian Alkaloids Pty Ltd","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Clozapine","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Tanner Pharma \/ Tasman Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Tanner Pharma \/ Tasman Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for CID2818

    Menu

    CID2818

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tanner Pharma

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Tanner Pharma

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Tasmanian Alkaloids Pty Ltd

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Tanner Pharma Group Signs Versacloz Distribution Agreement with Tasman Pharma Inc.

                            Details : Tanner to distribute Versacloz in areas outside of the U.S where the product is not yet registered. Versacloz is indicated for the treatment of severely ill patients with schizophrenia who fail to respond to standard antipsychotic treatment.

                            Brand Name : Versacloz

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 22, 2020

                            Lead Product(s) : Clozapine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Tasmanian Alkaloids Pty Ltd

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth